On going
- Phase II trial of atezolizumab (anti-PD-L1) in the treatment of patients with recurrent / refractory fungal infection / stage IIb-IV Cesarean section after previous systemic therapy (PARCT-1652)
- Data recording study for patients with cutaneous lymphomas (PROCLIPI)
- A multicenter, double-blind, randomized, placebo-controlled phase II test for the evaluation of Resminostat in the maintenance treatment of patients with advanced stage (stage IIB-IVB) Mycosis Fungoides (MF) or Sezary Syndrome (SS) who have of disease with systemic therapy (RESMAIN)
- Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL) REACH (Rash aEtiology After CHlormethine gel)
- Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)
Upcoming
- Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)
